ClinicalTrials.gg
CompletedNCT05273749RESILIENTUpdated Jan 22, 2025Results posted

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

A Phase 3 interventional study of TNX-102 SL Tablet, 5.6 mg and Placebo SL Tablet in Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 33 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
30th of 320
457 · median 72
Started
2022
with 12 others
Phase 3
55 of 369
2 open now
Registered
308th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 30th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2022, is one of 55 in phase 3, and was the 308th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Pain, Sleep, Fibromyalgia, FM
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is male or female 18 to 65 years of age, inclusive.
  • The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)

Exclusion criteria

Exclusion Criteria:

  • The patient has been diagnosed with infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attacks within past 2 years is exclusionary), or meets criteria for other type of systemic disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet, 5.6 mg

    1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL Tablet, 5.6 mg

  • Placebo comparator
    Placebo SL Tablet

    1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo SL Tablet

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.

    Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.

    Time frame: Baseline (Day -7 to Day -1), Week 14

Secondary outcomes

  1. Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint

    The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

    Time frame: Week 14

  2. Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint

    Change from Baseline in the FIQ-R Symptoms domain score at the Week 14 endpoint. Scores on the symptoms domain range from 0 to 90 where a higher score means worse outcome.

    Time frame: Day 1, Week 14

  3. Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint

    The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

    Time frame: Day 1, Week 14

  4. Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint

    The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

    Time frame: Day 1, Week 14

  5. Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint

    The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

    Time frame: Day 1, Week 14

  6. Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint

    Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

    Time frame: Baseline (Day -7 to Day -1), Week 14

07

Results

Posted Dec 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Started231226
Completed187179
Not completed4447
Withdrew: Adverse event148
Withdrew: Lack of efficacy28
Withdrew: Physician decision02
Withdrew: Withdrawal by subject1416
Withdrew: Lost to follow-up1010
Withdrew: Pregnancy10
Withdrew: Non-compliance32
Withdrew: Patient should not have been randomized due to ongoing unstable medical condition01

Outcome measures

PrimaryChange From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.

Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.

Time frame:
Baseline (Day -7 to Day -1), Week 14
Reported as:
Least squares mean · score on a scale
Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.-1.8 (-2.0 to -1.6)-1.2 (-1.4 to -0.9)
SecondaryProportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint

The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

Time frame:
Week 14
Reported as:
Count of participants · Participants
Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint
ParticipantsTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint6634
SecondaryChange From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint

Change from Baseline in the FIQ-R Symptoms domain score at the Week 14 endpoint. Scores on the symptoms domain range from 0 to 90 where a higher score means worse outcome.

Time frame:
Day 1, Week 14
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint-16.0 (-18.3 to -13.7)-8.4 (-10.7 to -6.1)
SecondaryChange From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint

The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

Time frame:
Day 1, Week 14
Reported as:
Least squares mean · score on a scale
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint-12.2 (-14.5 to -9.9)-6.8 (-9.2 to -4.4)
SecondaryChange From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint

The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

Time frame:
Day 1, Week 14
Reported as:
Least squares mean · T-score
Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint
T-scoreTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint-8.4 (-9.6 to -7.3)-4.2 (-5.3 to -3.1)
SecondaryChange From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint

The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

Time frame:
Day 1, Week 14
Reported as:
Least squares mean · T-score
Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint
T-scoreTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint-7.2 (-8.3 to -6.1)-4.2 (-5.3 to -3.1)
SecondaryChange From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint

Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

Time frame:
Baseline (Day -7 to Day -1), Week 14
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint-1.8 (-2.0 to -1.5)-1.2 (-1.4 to -1.0)

Adverse events

Collected over 14 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL Tablet, 5.6 mg0/231 (0%)2/231 (0.9%)78/231 (33.8%)
Placebo SL Tablet0/226 (0%)3/226 (1.3%)4/226 (1.8%)
Most frequent serious events
Most frequent serious events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Angina pectorisCardiac disorders0/2311/226
PneumoniaInfections and infestations0/2311/226
Muscular weaknessMusculoskeletal and connective tissue disorders0/2311/226
HypertensionVascular disorders0/2311/226
Coronary artery diseaseCardiac disorders0/2311/226
Pancreatitis acuteGastrointestinal disorders1/2310/226
Renal CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2310/226
Most frequent other events
Most frequent other events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Hypoaesthesia oralGastrointestinal disorders55/2311/226
Product taste abnormalProduct Issues27/2312/226
Paraesthesia oralGastrointestinal disorders16/2312/226
Tongue discomfortGastrointestinal disorders16/2310/226

Baseline characteristics

Safety population: all patients who took investigational product.

Age, Continuous
Age, Continuous(years)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Mean49.3 ± 10.4549.5 ± 11.249.4 ± 10.88
Sex: Female, Male
Sex: Female, Male(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Female224212436
Male71421
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Hispanic or Latino363571
Not Hispanic or Latino195190385
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
American Indian or Alaska Native213
Asian156
Native Hawaiian or Other Pacific Islander000
Black or African American322759
White194192386
More than one race213
Unknown or Not Reported000
08

Study locations

33 sites
  • Tonix Clinical Site
    Phoenix, Arizona 85012, United States
  • Tonix Clinical Site
    Oceanside, California 92056, United States
  • Tonix Clinical Site
    Santa Ana, California 92705, United States
  • Tonix Clinical Site
    Temecula, California 92591, United States
  • Tonix Clinical Site
    Cromwell, Connecticut 06416, United States
  • Tonix Clinical Site
    Fort Myers, Florida 33912, United States
  • Tonix Clinical Site
    Jacksonville, Florida 32256, United States
  • Tonix Clinical Site
    Miami Lakes, Florida 33016, United States
  • Tonix Clinical Site
    Ocala, Florida 34470, United States
  • Tonix Clinical Site
    Oldsmar, Florida 34677, United States
  • Tonix Clinical Site
    Orlando, Florida 32801, United States
  • Tonix Clinical Site
    Alpharetta, Georgia 30022, United States
  • Tonix Clinical Site
    Atlanta, Georgia 30329, United States
  • Tonix Clinical Site
    Evansville, Indiana 47714, United States
  • Tonix Clinical Site
    West Des Moines, Iowa 50265, United States
  • Tonix Clinical Site
    Prairie Village, Kansas 66208, United States
  • Tonix Clinical Site
    Covington, Louisiana 70433, United States
  • Tonix Clinical Site
    New Orleans, Louisiana 70115, United States
  • Tonix Clinical Site
    Prairieville, Louisiana 70769, United States
  • Tonix Clinical Site
    Boston, Massachusetts 02131, United States
  • Tonix Clinical Site
    Gulfport, Mississippi 39501, United States
  • Tonix Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Tonix Clinical Site
    Williamsville, New York 14221, United States
  • Tonix Clinical Site
    Cincinnati, Ohio 45219, United States
  • Tonix Clinical Site
    Tulsa, Oklahoma 74133, United States
  • Tonix Clinical Site
    Portland, Oregon 97210, United States
  • Tonix Clinical Site
    Charleston, South Carolina 29407, United States
  • Tonix Clinical Site
    Austin, Texas 78737, United States
  • Tonix Clinical Site
    Dallas, Texas 75231, United States
  • Tonix Clinical Site
    McKinney, Texas 75070, United States
  • Tonix Clinical Site
    Charlottesville, Virginia 22911, United States
  • Tonix Clinical Site
    Danville, Virginia 24541, United States
  • Tonix Clinical Site
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Nov 2023, 19 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2022
First posted
Mar 10, 2022
StartActual
Apr 6, 2022
Primary completionActual
Nov 14, 2023
CompletionActual
Nov 14, 2023
Results first posted
Dec 20, 2024
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05273749
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
Apr 6, 2022
Primary completion
Nov 14, 2023
Completion
Nov 14, 2023
Results posted
Dec 20, 2024
Last update
Jan 22, 2025

Study contacts

Gregory Sullivan, MD
study director · Tonix Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion